Zoetis Inc. is a global leader in the animal health industry, specializing in the discovery, development, manufacture, and commercialization of a wide range of products and services for animal health . The company offers medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for both companion animals and livestock across eight core species, including dogs, cats, horses, cattle, swine, poultry, fish, and sheep . Zoetis operates through two geographic segments, the United States and International, and markets its products directly to veterinarians and livestock producers in about 45 countries, while also contracting with distributors in regions where it does not have a direct commercial presence .
- Parasiticides - Provides treatments to protect animals from parasites, ensuring their health and well-being.
- Vaccines - Develops and manufactures vaccines to prevent diseases in various animal species.
- Dermatology - Offers products for the treatment and management of skin conditions in animals.
- Other Pharmaceuticals - Includes a range of pharmaceutical products for various health conditions in animals.
- Anti-infectives - Supplies medications to treat infections in animals, promoting recovery and health.
- Animal Health Diagnostics - Delivers diagnostic products and services to detect and monitor animal health issues.
- Medicated Feed Additives - Produces additives for animal feed to enhance health and growth.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Kristin C. Peck ExecutiveBoard | Chief Executive Officer and Director | Board of Directors at BlackRock, Board of Trustees at Mayo Clinic, Board of Directors at Catalyst, Member of Business Roundtable and The Business Council, Columbia Business School Board of Directors | CEO since January 2020, pivotal in Zoetis' IPO, led transformative initiatives. | View Report → |
Jamie Brannan Executive | Executive Vice President and Chief Commercial Officer | None | Joined Zoetis in 2016, strong commercial leadership, oversees global markets. | |
Jared Shriver Executive | President of U.S. Operations | None | Nearly 20 years at Zoetis, promoted to President of U.S. Operations in 2024. | |
Keith Sarbaugh Executive | Executive Vice President and Chief Digital & Technology Officer | None | Joined Zoetis in 2023, leads digital and technology strategy. | |
Nick Ashton Executive | Executive Vice President and President, Global Manufacturing and Supply | None | Joined Zoetis in 2020, extensive experience in production and supply chain. | |
Rimma Driscoll Executive | Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices | None | Joined Zoetis in 2016, leads business development and strategy. | |
Roxanne Lagano Executive | Executive Vice President, General Counsel, and Corporate Secretary | None | Joined Zoetis in 2012, extensive experience in HR and operations. | |
Wetteny Joseph Executive | Executive Vice President and Chief Financial Officer | None | CFO since June 2021, implemented strategic initiatives and cost-saving measures. | |
Antoinette R. Leatherberry Board | Director | Board Member at Digital Direct Holdings, STRIVE, American Family Insurance Mutual Holding Company, Widener University Board of Trustees, Boston University Board of Trustees, Ellig Group Advisory Board | Former Principal at Deloitte, expertise in technology transformations and governance. | |
Frank A. D’Amelio Board | Director | Board Member at Humana Inc., Hewlett Packard Enterprise, Catalent Inc., CFO in Residence at Deloitte CFO Academy | Former CFO of Pfizer, led major acquisitions and divestitures. | |
Gavin D.K. Hattersley Board | Director | President, CEO, and Director of Molson Coors Beverage Company | CEO of Molson Coors, extensive experience in consumer products and financial strategy. | |
Gregory Norden Board | Director | Board Member at NanoString Technologies, Praxis, Royalty Pharma | Former CFO of Wyeth, extensive experience in corporate finance and M&A. | |
Louise M. Parent Board | Director | Board Member at Fidelity National Information Services Inc. | Former EVP and General Counsel at American Express, expertise in governance and compliance. | |
Michael B. McCallister Board | Director and Board Chair | Board Member at AT&T, Fifth Third Bank | Former CEO of Humana, extensive experience in M&A and insurance product development. | |
Paul M. Bisaro Board | Director | Chair of the Board at Mallinckrodt plc, Board Member at Myriad Genetics, Inc. | Nearly 30 years in pharmaceutical industry, extensive M&A experience. | |
Robert W. Scully Board | Director | Board Member at KKR & Co. Inc., Chubb Limited | Over 30 years in financial services, expertise in M&A and strategic advice. | |
Sanjay Khosla Board | Director | Senior Fellow and Adjunct Professor at Kellogg School of Management, Senior Advisor for Boston Consulting Group, CEO of Bunnik LLC, Board Member at Igniting Consumer Growth Acquisition Company Limited and Qualsights | Over 35 years of international business experience, transformed Kraft Foods' developing markets. | |
Vanessa Broadhurst Board | Director | Executive Vice President, Global Corporate Affairs at Johnson & Johnson, Member of The Executive Leadership Council, Board member of the Ad Council | Director since July 2022, leads corporate affairs at Johnson & Johnson. | |
Willie M. Reed Board | Director | Dean of the College of Veterinary Medicine at Purdue University | Thought leader in animal health, extensive experience in veterinary medicine and diagnostics. |
-
Given the anticipated entry of new competitors in the dermatology space, particularly those with products carrying boxed warnings, what specific strategies is Zoetis implementing to defend market share for Apoquel and Cytopoint, and how might these strategies affect your promotional activities?
-
With the growth of alternative channels like retail and home delivery contributing significantly to sales (alternative channels were up 34% year-on-year in Q3), how is Zoetis adapting its sales and marketing strategy to address the shift away from traditional veterinary clinic visits, and what impact do you expect this to have on your relationships with veterinarians?
-
Considering that price contributed 6% to your 14% operational revenue growth in Q3 and that you anticipate the recent tailwinds from higher inflation to normalize, how do you plan to sustain your revenue growth as price-driven gains potentially decrease?
-
The MFA divestiture is expected to impact your Q4 revenue growth by reflecting a reduction of U.S. and international sales; can you elaborate on the magnitude of this impact and discuss the strategies you have in place to mitigate any negative effects on your overall financial performance?
-
You mentioned that headwinds in China have had approximately a 1% unfavorable impact on growth this year; could you provide more details on the specific challenges you're facing in the Chinese market and how you plan to address them to normalize growth in 2025?
Research analysts who have asked questions during Zoetis earnings calls.
Brandon Vazquez
William Blair & Company, L.L.C.
4 questions for ZTS
Jonathan Block
Stifel Financial Corp.
4 questions for ZTS
Michael Ryskin
Bank of America Merrill Lynch
4 questions for ZTS
Navann Ty
BNP Paribas S.A.
4 questions for ZTS
Christopher LoBianco
TD Cowen
3 questions for ZTS
Christopher Schott
JPMorgan Chase & Co.
3 questions for ZTS
Daniel Clark
Leerink Partners
3 questions for ZTS
David Westenberg
Piper Sandler
3 questions for ZTS
Erin Wright
Morgan Stanley
3 questions for ZTS
Andrea Alfonso
UBS
2 questions for ZTS
Balaji Prasad
Barclays
2 questions for ZTS
Chris Schott
JPMorgan Chase & Co.
2 questions for ZTS
Daniel Christopher Clark
Leerink Partners
2 questions for ZTS
Erin Wilson Wright
Morgan Stanley
2 questions for ZTS
Glen Santangelo
Jefferies
2 questions for ZTS
Jon Block
Stifel, Nicolaus & Company, Incorporated
2 questions for ZTS
Michael Riskin
Bank of America
2 questions for ZTS
Navann Ty Dietschi
BNP Paribas
2 questions for ZTS
Andrea Zayco Narvaez Alfonso
UBS
1 question for ZTS
Brandon Vasquez
William Blair & Company
1 question for ZTS
Chris
TD Cowen
1 question for ZTS
Kris Schott
JPMorgan Chase & Co.
1 question for ZTS
Russell Yuan
William Blair
1 question for ZTS
Sidharth Sahoo
HSBC
1 question for ZTS
Steve Scala
Cowen
1 question for ZTS
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Boehringer Ingelheim Animal Health Inc. | This competitor is part of the animal health division of Boehringer Ingelheim GmbH and is mentioned as one of the primary competitors in the animal health medicines, vaccines, and diagnostics market. |
This competitor is the animal health division of Merck & Co., Inc. and is identified as a primary competitor in the animal health industry. | |
This standalone animal health business is listed as a primary competitor in the animal health medicines, vaccines, and diagnostics market. | |
This company is highlighted as a primary competitor in the animal health diagnostics sector. |
| Customer | Relationship | Segment | Details |
|---|---|---|---|
U.S. Veterinary Distributor | Primary distributor of Zoetis products | All | Represents 14% of total revenue for 2024 , 15% for 2023 , and 14% for 2022. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
PetMedix Ltd. | 2023 | Zoetis acquired PetMedix Ltd. in Q3 2023 for an upfront cash consideration of $111 million plus up to $100 million in contingent payments to expand its portfolio of innovative antibody-based therapeutics for companion animals. |
adivo GmbH | 2023 | In Q3 2023, Zoetis completed the acquisition of adivo GmbH, a German R&D stage animal health company, with the transaction having no material impact on its condensed consolidated financial statements. |
Basepaws | 2022 | Zoetis completed the acquisition of Basepaws in Q2 2022, enhancing its precision animal health portfolio by adding genetic testing capabilities, including tests for 64 feline and over 210 canine health markers. |
Jurox | 2022 | On September 30, 2022, Zoetis acquired Jurox for a total purchase price of $226 million (with a net cash consideration of $215 million), integrating a comprehensive range of veterinary medicines for companion animals and livestock. |
Recent press releases and 8-K filings for ZTS.
- Net sales of $363.9 million for Q1 ended September 30, 2025, a 40% increase year-over-year.
- Net income of $26.5 million and diluted EPS of $0.65, up $19.6 million and $0.48, respectively, versus prior year.
- Adjusted EBITDA of $61.9 million, an increase of $31.2 million compared to Q1 FY2025.
- Raised full-year FY2026 adjusted EBITDA guidance to $230 million–$240 million and maintained net sales guidance of $1.43 billion–$1.48 billion.
- National launch of Restoris™ dental gel for dogs with periodontal disease to expand companion animal oral health portfolio.
- Market grew from $1.74 billion in 2024 to $2.19 billion in 2025 (CAGR 25.9%) and is projected to reach $5.46 billion by 2029 (CAGR 25.6%).
- Key growth drivers include rising neurological disorder prevalence, healthcare digitization initiatives, preventive healthcare adoption, aging populations, and demand for early disease detection.
- Emerging trends feature advanced neuroimaging, personalized diagnostic platforms, hybrid therapeutic-diagnostic solutions, big data analytics integration, and VR-based cognitive assessments.
- Competitive landscape is led by North America (2024), with major players like Viz.ai, Aidoc Medical, RapidAI, Qure.ai, Ceribell, BrainScope, and others; notable M&A includes SyntheticMR AB’s $5.03 million acquisition of Combinostics Oy in January 2025.
- Zoetis posted $2.4 billion in Q3 revenue, up 1% on a reported basis and 4% on an organic operational basis; adjusted net income was $754 million, up 5% reported and 9% organic.
- By segment, global companion animal revenue totaled $1.7 billion (up 2% organic), with the Simparica franchise at $356 million (+ 7%), key dermatology at $469 million (+ 3%) and OA pain at $138 million (– 11%); livestock revenue was $725 million, up 10% organic.
- Full-year guidance was narrowed: revenue of $9.4 billion–$9.475 billion (organic growth 5.5%–6.5%), adjusted net income of $2.8 billion–$2.84 billion (organic growth 5.5%–7%), and EPS maintained at $5.90–$6.00 reported and $6.30–$6.40 adjusted.
- Leadership update: R&D head Rob Polzer will retire end-February 2026, with Kevin Esch succeeding effective January 1, 2026.
- Zoetis posted $2.4 billion in Q3 revenue (+1% reported, +4% organic operational) and $754 million in adjusted net income (+5% reported, +9% organic operational).
- Companion Animal revenues were $1.7 billion, up 2% operationally; key franchises: Simparica $356 million (+7%), dermatology $469 million (+3%), while OA pain declined 11% to $138 million; livestock reached $725 million, up 10% organically.
- International revenue grew 6% organically: Simparica international $93 million (+22%), dermatology $162 million (+7%); OA pain international fell 3% to $80 million, and livestock grew 8%.
- Full-year 2025 guidance narrowed: organic operational revenue growth to 5.5–6.5%, organic operational adjusted net income growth to 5.5–7%, with revenue now expected at $9.40–$9.475 billion and adjusted net income at $2.80–$2.84 billion.
- Zoetis reported $2.4 billion in Q3 revenue (+1% reported; +4% organic operational) and $754 million in adjusted net income (+5% reported; +9% organic operational).
- Companion animal revenue reached $1.7 billion (+2% operationally), driven by parasiticide growth to $356 million (+7%) and dermatology to $469 million (+3%), offset by an 11% decline in OA pain to $138 million; livestock revenue grew 10% organically to $725 million.
- Adjusted gross margin expanded by 90 bps to 71.6%, and adjusted diluted EPS rose 7% operationally; foreign exchange added 20 bps to margins.
- Maintained 2025 full-year EPS guidance of $5.90–$6.00 reported and $6.30–$6.40 adjusted, while adjusting revenue guidance to $9.4–$9.475 billion (organic growth 5.5%–6.5%) and net income guidance to $2.8–$2.84 billion.
- Reported 4% revenue growth and 9% organic operational growth in adjusted net income (adjusted diluted EPS up 7% operationally, 12% organically).
- Parasiticides franchise grew 7% (Simparica Trio up 6%), dermatology up 3%, while OA pain declined 11% (Librela down 15%).
- Livestock segment delivered 10% organic operational growth globally (and 8% internationally) on broad‐based strength across species.
- Secured approvals for Linivi in Canada and positive EU opinion, plus EU approval for Portela; Solensia cat OA grew 9% to $18 M internationally; new long‐acting OA launches expected H1 2026.
- Raised full‐year 2025 guidance to $9.4–9.475 B revenue (organic growth 5.5–6.5%), adjusted net income $2.8–2.84 B, while maintaining adjusted diluted EPS at $6.30–6.40.
- Reported revenue of $2.4 billion in Q3, up 1% YoY, but down 4% on an organic operational basis (4% price, 0% volume).
- Adjusted net income of $754 million and adjusted diluted EPS of $1.70, up 5% and 8% reported YoY, yet down 9% and 12% on an organic operational basis, respectively.
- U.S. segment revenue grew 3% organically to $1.3 billion, while International segment revenue rose 6% organically to $1.1 billion.
- Key portfolio drivers included 10% organic growth in livestock revenue and 7% growth in the Simparica franchise in Q3.
- Full-year 2025 revenue guidance narrowed to $9.40–$9.475 billion with 5.5%–6.5% organic operational growth; adjusted EPS guidance maintained at $6.30–$6.40.
- Zoetis reported Q3 revenue of $2.4 billion, up 1% y-o-y, with 4% organic operational growth.
- Net income was $721 million ($1.63 per diluted share), up 6% y-o-y; adjusted net income was $754 million ($1.70 per diluted share), up 5% y-o-y.
- U.S. segment revenue was $1.3 billion (–2% reported, +3% organic), while International revenue was $1.1 billion (+3% reported, +6% organic).
- Full year 2025 guidance revised to $9.400–$9.475 billion in revenue (5.5–6.5% organic growth), narrows adjusted net income growth to 5.5–7.0%, and maintains adjusted EPS at $6.30–$6.40.
- Zoetis reported Q3 2025 revenue of $2.4 B, up 1% YoY, with 4% organic operational growth.
- Net income was $721 M, or $1.63 diluted EPS (up 6% and 9%, respectively), and adjusted net income was $754 M, or $1.70 EPS (+5% and 8% reported; +9% and 12% organically).
- U.S. segment revenue: $1.3 B (–2% reported; +3% organic); International segment revenue: $1.1 B (+3% reported; +6% organic).
- Revised full-year 2025 guidance to $9.400–$9.475 B in revenue (organic growth 5.5%–6.5%), narrowed adjusted net income growth to 5.5%–7.0%, and maintained adjusted EPS at $6.30–$6.40.
- Zoetis has received Health Canada approval for Lenivia® (izenivetmab injection), the world’s first long-acting canine anti-nerve growth factor monoclonal antibody therapy to alleviate osteoarthritis pain in dogs for three months per dose.
- Approval follows a nine-month field study showing dogs experienced increased mobility and decreased pain after a single injection.
- Lenivia is administered subcutaneously once every three months and complements Zoetis’s existing OA pain portfolio alongside Librela®.